Fig. 6
[89Zr]Zr-cetuximab imaging monitored TNBC PDX response after dasatinib treatment. PDX-bearing mice treated with dasatinib (right) or vehicle (left) for 5 days were administered [89Zr]Zr-cetuximab on the last day of treatment and imaged at 48 h p.i. (a). [89Zr]Zr-cetuximab tumor VOIs demonstrate higher uptake of the tracer in treated mice compared to control (b). The tumor growth rate was compared using linear mixed-effects models on log-transformed data and the p values were adjusted for multiplicity using the Holm procedure (c). The asterisk indicates a significant difference and the error bars represent 95% confidence intervals. A plot of the tumor uptake of the tracer vs. %Δ tumor volume exhibited a strong, direct association wherein higher the tracer uptake correlated with higher tumor regression (d). L = liver. Tumors were identified by a white circle